Start With ‘Why' When Adopting New Tech To Support Hybrid Decentralized Trials

By Nicole Latimer, Chief Executive Officer

During the height of the COVID-19 pandemic, clinical trial sites appeared to face an existential threat as the industry discussed “siteless” decentralized trials. Two years later, conventional wisdom recognizes the importance of face-to-face interactions in clinical care and suggests that hybrid decentralized trials will grow faster ^[1] and be more prevalent ^[2] than fully decentralized ones. For sites, however, the rise of hybrid decentralized trials introduces another challenge: the adoption of new technologies.